Epstein Secrets

led in Feb (unchanged from Jan vs estimate 40.6%) Marks & Spencer gains the most in six months as sales fall less than estimated (trading 45.47%) Novartis asks EU regulators to approve the Prexige pain pill that was pulled off the market 4 years ago German factory orders climb almost 5x faster than es

From: Ike Groff <MI > Subject: early tour 4.6.11 Date: Wed, 06 Apr 2011 10:39:14 +0000 Good Morning ... European Markets up 0-70 bps... Nikkei Closed -32 bps (Han

r Newspaper Articles s Stories Barron's cover: Discusses the state of the US housing market Barron's< Barron's positive: Total (FP FP) Barron's< Novartis (NVS) Barron's< Qualcomm (QCOM) Barron's< Global Markets Inc IPO (BATS) Barron's< Wall Street Keys On Landlord Business WSJ mod=ITP_pageone_0

From: Ike Groff Subject: Early Tour 3.19.12 Date: Mon, 19 Mar 2012 10:13:14 +0000 Good Morning European Markets off 0-55 bps (Spain +70 bps)... Nikkei Closed +0.

ivity Yesterday: EFA (50.31 -0.1%)- Bullish customer bought 75,418 Dec 53 calls for $1.52 ($11.46mm in premium). Top 5 components are Nestle, HSBC, Novartis and BP. AIG (31.72 +0.5%) - A customer bot 9,352 $32c that expire friday for .60. Earnings 8/2. GLD ($157.43 -0.1%)- A customer expecting to see a

rata EGM to vote on Glencore deal September 12 - Germany's Constitutional Court ruling on ESM S, Fiscal Pact November 6 - US Presidential Election Ike Groff Stamford, CT 069011 e• mailto: (Description: Description: cid:[email protected]) This e-mail and any files transmitted with it are c

ar, LFL's strong (trading -0.16%) • Astrazeneca eps slightly lower than estimates, maintains guidance, pipeline update positive (trading +4.0%) • Novartis O1 core eps and net meet estimates, fx impact, sales miss, guidance reiterated (trading -1.1%) • Novozymes Q1 beats estimates, now sees 2014 net pr

From: Ike Groff Subject: Early Tour 4.24.14 Date: Thu, 24 Apr 2014 09:52:42 +0000 Inline-Images: image00 Ljpg; image002.png ,Description: Description: Good Mor

close). And now Novartis & GSK have announced a major series of transactions: creating new consumer-health venture (GSK 63.5% controlling interest), Novartis agrees to buy GSK's oncology unit for as much as $16B, Novartis to sell vaccines unit to Glaxo for $7.1B, Novartis to sell Animal Health unit to El

From: Ike Groff Subject: Early Tour 4.22.14 Date: Tue, 22 Apr 2014 09:50:50 +0000 Inline-Images: image00 1 jpg; image002.png ID:Description: Description: Good M

e reporting inline with recent pre-announcement and guiding touch lower). Healthcare +1.28% & Food/Beverages +0.72% also outperforming in Europe as Novartis +3.8% & Unilever +2.4% break-out after reporting solid numbers. Volumes heavy across the region with Estoxx600 turnover currently —130% of 3-month a

From: Ike Groff Subject: Early Tour 1.23.13 Date: Wed, 23 Jan 2013 11:01:01 +0000 Inlinc-Images: image00 1 jpg; image002.png ;Description: Description: Good Mo